| 本文已被:浏览 3073次 下载 3067次 |
 码上扫一扫! |
| 沙库巴曲缬沙坦治疗老年顽固性心力衰竭疗效优势的Meta分析 |
| 苗依婷1,2,葛亚龙3,黄晶2,贺雪梅2,赵萱2,4,柴程程2,蒋东洋2,梁英2 |
|
|
| (1.山东第二医科大学临床医学院,山东 潍坊 261000;2.山东第一医科大学第一附属医院<山东省千佛山医院>全科医学科,山东 济南 250014;3.济南市第三人民医院心血管内科,山东 济南 250132;4.济宁医学院临床医学院,山东 济宁 272013) |
|
| 摘要: |
| 目的 系统评价沙库巴曲缬沙坦(ARNI)对比肾素-血管紧张素-醛固酮系统(RAAS)抑制剂(ACEI/ARB)在治疗老年顽固性心力衰竭(RHF)患者的疗效和安全性。方法 检索英文数据库(Pubmed、Embase、Web of science、the Conchrane Library)及中文数据库(知网、万方、维普、CBM)中已发表的随机对照试验(RCTs),采用Cochrane风险评估工具对文献质量进行评价,采用RevMan及Stata软件进行Meta分析。结果 纳入10篇文献共1 118例老年RHF患者。结果显示,应用ARNI组(研究组)氨基末端脑钠尿肽前体(NT-proBNP)(MD=-282.61,95%CI -344.56 ~ -220.66,P﹤0.05)、左心室舒张末期内径(LVEDD)(MD=-3.48,95%CI -4.58 ~ -2.39,P﹤0.05)低于应用ACEI/ARB组(对照组);左心室射血分数(LVEF)(MD=6.35,95%CI 4.65 ~ 8.06,P﹤0.05)、有效率(OR=2.449,95%CI 1.851~ 3.241,P﹤0.05)明显高于对照组。两组肾功能损害、头晕、高血钾比较无差异,低血压发生率低于对照组。结论 与ACEI/ARB相比,ARNI可显著改善心室重构,进一步改善老年RHF患者心功能,并且安全性良好。 |
| 关键词: 顽固性心力衰竭 老年 沙库巴曲缬沙坦 肾素-血管紧张素-醛固酮系统抑制剂 Meta分析 |
| DOI:10.13506/j.cnki.jpr.2024.04.016 |
| 基金项目: |
|
出版日期:2024-04-25
|
|
| Meta-analysis of sacubitril-valsartan versus renin-angiotensin-aldosterone system inhibitors in the treatment of elderly refractory heart failure |
| MIAO Yiting1,2,GE Yalong3,HUANG Jing2,HE Xuemei2,ZHAO Xuan2,4,CHAI Chengcheng2,JIANG Dongyang2,LIANG Ying2 |
| (1.School of Clinical Medicine, Shandong Second Medical University, Weifang 261000,China;2.Department of General Practice,the First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital,Jinan 250014,China;3.Department of Cardiovascular,Jinan Third Hospital, Jinan 250101,China;4.School of Clinical Medicine, Jining Medical University,Jining 272013,China) |
| Abstract: |
| Objective To systematically evaluate the efficacy and safety of sacubitril-valsartan(ARNI) compared to angiotensin converting enzyme inhibitors/angiotensin II receptor antagonists(ACEI/ARB)in the treatment of elderly refractory heart failure patients.Methods The literatures were obtained in The Cochrane Library, Embase, PubMed, Web of science and Chinese databases (CNKI, VIP ,WanFang and CBM). After literature screening and data extraction, the quality of the included literature was evaluated using the Cochrane bias risk assessment tool. Meta analysis was conducted using RevMan and Stata software.Results A total of 10 literatures were included, with a total of 1 118 elderly refractory heart failure patients including. Meta-analysis results showed that the N-terminal proBNP(NT-proBNP)(MD=-282.61,95%CI -344.56~ -220.66,P﹤0.05), the left ventricular end-diastolic diameter(LVEDD)(MD=-3.48,95%CI -4.58~ -2.39,P﹤0.05) in the study group were lower than those in the control group; the left ventricular ejection fraction (LVEF)(MD=6.13, 95%CI 5.15~7.11, P<0.05) and effective rate (OR=2.548, 95%CI 2.058~3.154, P<0.05) were significantly higher than those in the control group, respectively. The left ventricular ejection fraction (LVEF) (MD=6.35,95%CI 4.65~8.06,P﹤0.05) and effective rate (OR=2.449,95%CI 1.851—3.241,P﹤0.05) were significantly higher than those in the control group. In terms of adverse reactions, there was no difference in renal function damage, dizzy and hyperkalemia between the two groups, and the incidence of hypotension in the study group was lower than that in the control group.Conclusion Compared with ACEI/ARB, sacubitril-valsartan can significantly improve cardiac function, improve ventricular remodeling, and reduce myocardial tissue damage in elderly patients with refractory heart failure without significant adverse reactions. |
| Key words: Refractory Heart Failure elderly sacubitril-valsartan renin-angiotensin-aldosterone system inhibitors Meta-analysis |